Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome

The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive efficacy (achievement of target blood pressure in 76% of patients) and good safety profile, provides a complex effect on specific markers of inflammation and disorders of carbohydrate metabolism. The study showed a decrease in the high-sensitivity C-reactive protein (hs-CRP) from 3.15 (2.0; 4.18) mg/l to 2.3 (1.18; 4.03) mg/l (p = 0.001), intercellular adhesion molecules (iCAM-1) from 330,23 (295.7; 387.3) ng/ml to 310.07 (252.72; 370.4) ng/ml (p = 0.044) with no adverse effect on insulin resistance, as well as a reduction in the adipokine activity and overall cardiovascular risk.

артериальная гипертензия, АГ, метаболический синдром, фармакотерапия АГ, антигипертензивные препараты, маркеры воспаления, инсулинорезистентность, сердечно-сосудистый риск, бета-адреноблокаторы, небиволол, Небилет, arterial hypertension, AH, metabolic syndrome, AH therapy, antihypertensive drugs, inflammatory markers, insulin resistance, cardiovascular risk, beta-blockers, nebivolol, nebilet

1. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab, 2001, Feb., 86 (2): 713-8.

2. Boden-Albala B, Suzuki T, Hirata K et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J., 2008, Aug., 156 (2): 405-10.

3. Ройтберг Г.Е., Дорож Ж.В., Курукшина О.В. Роль адипокинов в прогрессировании метаболических нарушений у пациентов без ожирения с инсулинорезистентностью. Профилактическая медицина, 2010, 5: 23-26.

4. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav,, 2008, May 23, 94 (2): 206-18.

5. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb VascBiol., 2008, Jun., 28 (6): 1039-49.

6. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am., 2007, Nov., 91 (6): 1063-77.

7. Gustafson B, Hammarstedt A, Andersson CX, et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol., 2007, Nov., 27 (11): 2276-83.

8. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost, 2008, Jun., 99 (6): 995-1000.

9. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31 (7): 1281-1357.

10. «Диагностика и лечение артериальной гипертонии». Клинические рекомендации МЗ РФ, 2013 г. http://cardioweb.ru/ klinicheskie-rekomendatsii

11. Elliot WJ, Meyer PM. Incident diabet s in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet, 2007, 369: 207-10.

12. Морозова Т.Е., Андрущишина Т.Б., Ошорова С.Д., Латыйпова Е.Р. Гемодинамические и метаболические эффекты ингибитора ангиотензинпревращающего фермента зофеноприла у мужчин и женщин с артериальной гипертензией и ожирением. Проблемы женского здоровья, 2013, 2: 5-10.

13. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich), 2009, Jun., 11 (6): 309-15.

14. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med, 2000, 342: 905-912.

15. Sharma AM, Pischon T, Hardt S et al. Hypothesis: beta-adrenergic receptor blockers and weight gain:systematic analysis. Hypertension, 2001, 37: 250-254.

16. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin., 2010, Mar., 26 (3): 615-29.